APP and Dravet syndrome: Notably, targeting APP expression with antisense oligonucleotides (ASOs) has been shown to restore mitochondrial function in DS astrocytes, highlighting APP dosage as a key upstream driver of mitochondrial and neurodegenerative pathology—and a promising therapeutic target for both DS and AD [105].